J1I-MC-GZBO

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

• IRAS ID

  1009277

• Contact name

  Veronica Acevedo

• Contact email

  EU_lilly_clinical_trials@lilly.com

• Sponsor organisation

  Eli Lilly and Co.

• Research summary

  Lay Summary will be provided

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  24/LO/0135

• Date of REC Opinion

  15 Mar 2024

• REC opinion

  Further Information Favourable Opinion